Arbutus biopharma and vaccitech announce clinical trial collaboration agreement to evaluate rnai therapeutic, ab-729, in combination with immunotherapeutic, vtp-300, in subjects with chronic hepatitis b virus infection

Warminster, pa. and oxford, united kingdom, july 06, 2021 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) and vaccitech plc (nasdaq: vacc) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis b virus (hbv) infection (chb) who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (nrti) therapy.
ABUS Ratings Summary
ABUS Quant Ranking